Patient characteristics
| Visits with MI | Visits without MI | |
| Number of visits | 2686 (9.7) | 25 123 (90) |
| Age (years), median (IQR) | 76 (66–84) | 71 (60–81) |
| Women | 1073 (40) | 10 999 (44) |
| Comorbidities | ||
| Prior MI | 1213 (45) | 6411 (26) |
| Prior revascularisation | 1059 (39) | 6719 (27) |
| Prior stroke | 419 (16) | 3022 (12) |
| Heart failure | 7968 (32) | 957 (36) |
| Diabetes | 890 (33) | 6407 (26) |
| Hypertension | 2020 (75) | 16 693 (66) |
| Atrial fibrillation | 731 (27) | 8095 (32) |
| Dialysis | 77 (2.9) | 321 (1.3) |
| COPD | 382 (14) | 3839 (15) |
| Laboratory data | ||
| First hs-cTnT concentration (ng/L), median (IQR) | 55 (27–161) | 14 (8–26) |
| Historical hs-cTnT concentration, (ng/L), median (IQR) | 16 (9–33) | 9 (5–18) |
| Relative change between historical and first hs-cTnT concentration, median (IQR) | 166% (52–602) | 29% (14–63) |
| Haemoglobin (g/L), median (IQR) | 132 (119–145) | 135 (123–146) |
| Nt-pro-BNP (ng/L), median (IQR) | 2480 (664–6593) | 1020 (280–3334) |
| eGFR (mL/min/1.73 m2): | ||
| >60 | 1510 (56) | 17 113 (68) |
| 30–59 | 882 (12) | 6574 (26) |
| <30 | 292 (11) | 1439 (5.7) |
| Medications | ||
| Aspirin | 1507 (56) | 10 374 (41) |
| P2Y12 inhibitors* | 460 (17) | 2850 (11) |
| Any platelet inhibitor† | 1653 (62) | 11 585 (46) |
| Beta-blockers | 1686 (63) | 14 391 (57) |
| ACEi/ARB | 1497 (56) | 12 719 (51) |
| Statins | 1336 (50) | 10 563 (42) |
| DOAC | 76 (2.8) | 1018 (4.1) |
| OAC‡ | 386 (14) | 4891 (19) |
| Warfarin | 317 (12) | 3961 (16) |
| Mortality within 30 days | ||
| All-cause mortality | 163 (6.1) | 424 (1.7) |
| Cardiovascular mortality | 126 (4.7) | 214 (0.9) |
| Non-cardiovascular mortality | 37 (1.4) | 210 (0.8) |
Data are presented as n (%), or median with IQR.
*Includes treatment with clopidogrel, ticagrelor, dipyradimole or prasugel.
†Includes treatment with aspirin or P2Y12 inhibitors.
‡Includes treatment with NOAC or warfarin.
ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; DOAC, direct oral anticoagulants; eGFR, estimated glomerular filtration rate; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; Nt-pro-BNP, N-terminal pro b-type natriuretic peptide; OAC, oral anticoagulants.